Eurofins stock gets higher Citi target as growth outlook softens

Eurofins Scientific faces a more cautious 2026 growth outlook, while Citi has raised its price target for the laboratory-testing group. Markets Insider reported on Friday, October 30, that Citi lifted its target to 87.50 euros from 73.70 euros and retained a Neutral rating.

Eurofins stock traded at 87.60 euros on Lang & Schwarz at 18:24:41 CET on Monday, November 2, 2026. Investors can follow the real-time quote of Eurofins stock.

Growth improves while guidance softens

Eurofins reported revenue of 5.614 billion euros for the first nine months of 2026, up 3.7 percent from the prior-year period. Organic growth improved sequentially from 2.5 percent in the first quarter to 3.0 percent in the second and 3.5 percent in the third quarter.

That operating improvement has not restored the previous full-year objective. Eurofins expects 2026 organic growth to fall below its earlier mid-single-digit target, citing slower-than-normal market conditions and clinical programs that are not expected to restart this year.

Acquisition revenue is expected to exceed the previous annualized objective of 250 million euros. Citi's higher target therefore arrives as investors weigh acquisition execution and a possible recovery in clinical demand against softer underlying growth.

Margin goals remain an anchor

The company has maintained its 2026 profitability and cash-flow objectives. Eurofins also retains a 24 percent adjusted EBITDA margin objective for 2027, compared with an adjusted EBITDA margin of 22.5 percent in 2025.

Markets Insider reported the analyst action, while Eurofins published its nine-month trading update on October 21 before the opening of Euronext Paris.

French market conditions remain linked to the CAC 40.

More news and analyses on Eurofins Scientific stock